Surnar Bapurao, Jayakannan Manickam
Department of Chemistry, Indian Institute of Science Education and Research (IISER) Pune, Dr. Homi Bhabha Road, Pune 411008, Maharashtra, India.
ACS Biomater Sci Eng. 2016 Nov 14;2(11):1926-1941. doi: 10.1021/acsbiomaterials.6b00310. Epub 2016 Sep 30.
Biodegradable block copolymer chemical structures were engineered as drug nanocarriers to precisely program the enzyme-controlled release of anticancer drugs at intracellular compartments in cancer cells. New classes of amide and ester side chain-substituted caprolactone monomers were designed by multistep organic synthesis and polymerized under ring opening processes to make new classes of substituted polycaprolactone--polyethylene glycol copolymers. These block copolymers were self-assembled as stable nanoparticles of <200 nm in water. The polymer nanoparticles were found to be excellent scaffolds for loading a wide range of anticancer drugs and stabilized them at extracellular circulating conditions (37 °C in PBS). At the intracellular level, lysosomal-esterase enzyme biodegraded the aliphatic polyester PCL backbone and facilitated the release of drugs in a steady and controlled manner. In vitro drug release studies confirmed that the amide-PCL block copolymers exhibited controlled drug release compared to that of their non-hydrogen-bonded ester-PCL blocks or unsubstituted PCL blocks. The influence of hydrogen bonding interactions on the drug release profiles of PCL nanoparticles were studied by FT-IR and time-resolved fluorescent decay measurements. Cytotoxicity experiments in cervical cancer (HeLa) and breast cancer (MCF-7) cell lines demonstrated that amide diblock copolymer nanoassemblies show slow and prolonged cell killing. The new block copolymers were capable of loading multiple anticancer drugs like doxorubicin (DOX), curcumin (CUR), camptothecin (CPT), and methotrexate (MTX) that largely differ in pharmacokinetics as well as fluorescent regions for cellular imaging. Interestingly, these different drugs could be delivered to the intracellular compartments of the cancer cells by an identical enzyme-controlled delivery pathway from a single biodegradable block copolymer nanoscaffold. Confocal microscopic images exhibited that the engineered block copolymer nanoparticles were capable of transporting all of these drugs across the cell membrane and accumulating them predominantly in the cytoplasm and peri-nuclear region. The present investigation presents a new opportunity in the structural engineering of biodegradable diblock copolymer nanoassemblies for enzyme-controlled multiple-anticancer-drug administration in cancer therapy.
可生物降解的嵌段共聚物化学结构被设计为药物纳米载体,以精确控制抗癌药物在癌细胞内特定区域的酶控释放。通过多步有机合成设计了新型的酰胺和酯侧链取代的己内酯单体,并在开环过程中进行聚合,以制备新型的取代聚己内酯-聚乙二醇共聚物。这些嵌段共聚物在水中自组装成稳定的、直径小于200 nm的纳米颗粒。研究发现,聚合物纳米颗粒是负载多种抗癌药物的优良支架,并能在细胞外循环条件下(37℃,PBS缓冲液)使药物稳定。在细胞内水平,溶酶体酯酶可降解脂肪族聚酯PCL主链,并以稳定且可控的方式促进药物释放。体外药物释放研究证实,与非氢键连接的酯-PCL嵌段或未取代的PCL嵌段相比,酰胺-PCL嵌段共聚物表现出可控的药物释放特性。通过傅里叶变换红外光谱(FT-IR)和时间分辨荧光衰减测量研究了氢键相互作用对PCL纳米颗粒药物释放曲线的影响。在宫颈癌(HeLa)和乳腺癌(MCF-7)细胞系中进行的细胞毒性实验表明,酰胺二嵌段共聚物纳米组装体具有缓慢且持久的细胞杀伤作用。新型嵌段共聚物能够负载多种抗癌药物,如阿霉素(DOX)、姜黄素(CUR)、喜树碱(CPT)和甲氨蝶呤(MTX),这些药物在药代动力学以及细胞成像荧光区域方面差异很大。有趣的是,这些不同的药物可以通过相同的酶控递送途径,从单一的可生物降解嵌段共聚物纳米支架递送至癌细胞的细胞内区域。共聚焦显微镜图像显示,设计的嵌段共聚物纳米颗粒能够将所有这些药物转运穿过细胞膜,并主要在细胞质和核周区域积累。本研究为可生物降解二嵌段共聚物纳米组装体的结构工程提供了新的契机,可用于癌症治疗中酶控多抗癌药物给药。